TXG 10x Genomics, Inc.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.…
Industry Peers
Medical DevicesKey Statistics
About 10x Genomics (NASDAQ: TXG)
›
10x Genomics (NASDAQ: TXG) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 1,178 employees.
The shares were at 51.80 USD on 20 November 2026, up 298.5% over 52 weeks. Its 52-week range is 13.58 USD to 102.81 USD: the price is 49.6% below the high and 281.4% above the low.
Its market capitalisation is 6.81B USD.
10x Genomics reports return on equity of -5.5%, an operating margin of -10.6% and revenue up 1.1% year over year.
It holds more cash than debt, a net cash position of 499.89M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 68.14 USD is 31.5% above the current price. The next earnings report is expected on 11 February 2027.